We are live on
!
Find out more
ARTA
A.R.T. Advisors Portfolio holdings
AUM
$1.79M
1-Year Est. Return
57.47%
This Fund
S&P 500
This Quarter
Est. Return
+27.4%
1 Year Est. Return
+57.47%
3 Year Est. Return
+81.79%
5 Year Est. Return
+178.88%
10 Year Est. Return
–
AUM
$21.6M
AUM Growth
+$3.9M
(+22%)
Cap. Flow
+$1.75M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
30.06%
Holding
126
New
58
Increased
4
Reduced
8
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$809K |
| 2 |
Merck
MRK
|
+$736K |
| 3 |
ExxonMobil
XOM
|
+$731K |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$648K |
| 5 |
United Airlines
UAL
|
+$623K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$1.61M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$1.04M |
| 3 |
Delta Air Lines
DAL
|
+$846K |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$501K |
| 5 |
Costco
COST
|
+$395K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.61% |
| 2 | Consumer Discretionary | 11.06% |
| 3 | Industrials | 10.97% |
| 4 | Energy | 10.3% |
| 5 | Technology | 9.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ExxonMobil
XOM
$650B
| $804K | 3.72% |
+19,495
| New | +$731K |
|
|
2
Merck
MRK
$324B
| $751K | 3.48% |
+9,617
| New | +$736K |
|
|
3
Regeneron Pharmaceuticals
REGN
$69.8B
| $724K | 3.35% |
+1,498
| New | +$809K |
|
|
4
Vertex Pharmaceuticals
VRTX
$122B
| $667K | 3.09% |
+2,824
| New | +$648K |
|
|
5
United Airlines
UAL
$38.8B
| $666K | 3.08% |
+15,390
| New | +$623K |
|
6
Verizon
VZ
$190B
| $654K | 3.03% |
11,125
-1,100
| -9% | -$65.3K |
|
7
Arrow Electronics
ARW
$10.9B
| $588K | 2.72% |
+6,044
| New | +$535K |
|
8
Baxter International
BAX
$11.6B
| $569K | 2.63% |
+7,089
| New | +$562K |
|
9
AbbVie
ABBV
$457B
| $552K | 2.56% |
+5,151
| New | +$495K |
|
10
Denali Therapeutics
DNLI
$3.66B
| $517K | 2.39% |
+6,173
| New | +$373K |
|
11
Best Buy
BBY
$18B
| $506K | 2.34% |
+5,074
| New | +$567K |
|
|
12
Johnson & Johnson
JNJ
$632B
| $504K | 2.33% |
3,202
-10,900
| -77% | -$1.61M |
|
13
Gilead Sciences
GILD
$161B
| $478K | 2.21% |
+8,200
| New | +$495K |
|
14
ConocoPhillips
COP
$146B
| $436K | 2.02% |
+10,900
| New | +$402K |
|
15
Alphabet (Google) Class A
GOOGL
$3.92T
| $429K | 1.99% |
+4,900
| New | +$412K |
|
16
Boeing
BA
$166B
| $427K | 1.98% |
+1,997
| New | +$384K |
|
17
Novartis
NVS
$295B
| $411K | 1.9% |
+4,349
| New | +$380K |
|
|
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
| $394K | 1.82% |
2,519
-3,900
| -61% | -$501K |
|
|
COOP
19
DELISTED
Mr. Cooper
COOP
| $377K | 1.75% |
+12,159
| New | +$311K |
|
20
Goldman Sachs
GS
$315B
| $372K | 1.72% |
1,411
+100
| +8% | +$22.3K |
|
21
Booking.com
BKNG
$138B
| $370K | 1.71% |
+4,150
| New | +$320K |
|
22
ArcelorMittal
MT
$50.7B
| $365K | 1.69% |
+15,940
| New | +$279K |
|
23
NextEra Energy
NEE
$186B
| $357K | 1.65% |
+4,632
| New | +$346K |
|
24
Celsius Holdings
CELH
$6.94B
| $348K | 1.61% |
+20,730
| New | +$207K |
|
25
Magnite
MGNI
$2.68B
| $343K | 1.59% |
+11,181
| New | +$169K |
|
Similar funds
MA
FFIM
LC
YEPV
AAM
CCM
IR
IFC
A.R.T. Advisors's Q4 2020 Portfolio in Review
As of Q4 2020, A.R.T. Advisors held 126 positions worth $21.6M, up 22% from $17.7M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
A.R.T. Advisors deployed $1.75M of net new capital in Q4 2020, opening 58 new positions and adding to 4 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 1,498 shares worth $724K.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 29% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $1.61M trimmed.
- A.R.T. Advisors's largest Q4 2020 buy was Regeneron Pharmaceuticals: 1,498 shares worth $724K.
- A.R.T. Advisors added most to Ford in Q4 2020, an estimated $80.4K increase.
- A.R.T. Advisors's biggest Q4 2020 reduction was Johnson & Johnson, cutting an estimated $1.61M.
- A.R.T. Advisors fully exited Bristol-Myers Squibb in Q4 2020, selling an estimated $1.04M.
- A.R.T. Advisors's ten largest holdings make up 30% of its $21.6M portfolio in Q4 2020.
- A.R.T. Advisors opened 58 new positions and closed 54 in Q4 2020.
- A.R.T. Advisors's portfolio value rose 22% quarter-over-quarter to $21.6M.
Based on A.R.T. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.